Two Sigma Securities’s Summit Therapeutics SMMT Stock Holding History

Two Sigma Securities’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,149	Closed	-$280K	–	1949
2025 Q2	$280K	Buy	+13,149	New	+$300K	0.03%	698
2022 Q4	–	Sell	-17,092	Closed	-$20K	–	3203
2022 Q3	$20K	Buy	+17,092	New	+$19.3K	﹤0.01%	2298
2022 Q1	–	Sell	-19,474	Closed	-$52K	–	2472
2021 Q4	$52K	Buy	+19,474	New	+$93.6K	﹤0.01%	1271

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Two Sigma Securities's SMMT Position: Q3 2025 in Review

Two Sigma Securities sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 13,149 shares — an estimated $280K sold.

Two Sigma Securities first reported a position in SMMT in Q4 2021 and held it in 3 quarters. The position peaked at $280K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Two Sigma Securities reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Two Sigma Securities sold 13,149 Summit Therapeutics shares in Q3 2025, an estimated $280K.
Two Sigma Securities first reported a position in Summit Therapeutics in Q4 2021 and held it in 3 quarters.
Two Sigma Securities's Summit Therapeutics position peaked at $280K in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.